ReNeuron Group plc Presents new exosome data at major conference (2515E)
May 05 2017 - 1:00AM
UK Regulatory
TIDMRENE
RNS Number : 2515E
ReNeuron Group plc
05 May 2017
AIM: RENE 5 May 2017
ReNeuron Group plc
ReNeuron presents new data with its exosome therapy programme at
major scientific conference
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based
global leader in the development of cell-based therapeutics, is
pleased to announce that it will today be presenting new data
relating to the characterisation and scale-up of its CTX
cell-derived exosome therapy candidates at a leading scientific
conference in London.
In a poster presentation, ReNeuron researchers and their
academic collaborators at the Department of Biochemical
Engineering, University College London, address the challenges of
purifying CTX-derived exosomes at scale whilst preserving their
potential therapeutic attributes to ensure consistency of future
manufacture. New strategies are presented to address the upstream
cell culture processes needed to generate the exosomes and the
downstream purification methods that can be applied to remove
protein and DNA-based impurities from the exosomes at commercially
relevant scale. These new methods yielded a three-fold increase in
particle protein purity and a more than five-fold increase in
particle DNA purity compared with previous purification
processes.
In a further poster presentation, research teams at ReNeuron and
at the UK's Cell and Gene Therapy Catapult address the challenge of
characterising ReNeuron's CTX cell-derived exosomes to ensure
consistency and control during manufacture. The studies undertaken
demonstrated a robust approach to optimising and qualifying assays
for micro-RNA ("miRNA") targets found in the exosomes. A potential
advantage of exosomes when utilised as a carrier for the delivery
of therapeutic miRNAs in gene therapy is the avoidance of issues
typically encountered by RNA-based drugs such as stability in vivo
and tissue targeting.
The application of robust characterisation and purification
methods to ReNeuron's exosome populations will support future
development of the Company's exosome-based therapeutic candidates
across multiple potential disease indications, the initial disease
target being cancer.
The above data are being presented today at the International
Society for Cellular Therapy (ISCT) 2017 Annual Meeting in London.
ReNeuron's Chief Executive Officer, Olav Hellebø, will also be
speaking on "Commercialisation requirements for cell and gene
therapies" in a plenary session at the conference. Further
information about this conference may be found at
www.isct2017.com.
Dr Randolph Corteling, Head of Research at ReNeuron, said:
"The data being presented at the ISCT 2017 conference represent
key advances in the development of ReNeuron's CTX-derived exosome
therapeutic programme, both as a potential new nanomedicine
targeting cancer and as a potential delivery system for gene
therapy treatments. We look forward to presenting further data from
this programme in the months ahead."
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for motor disability as a result of stroke, for
critical limb ischaemia and for the blindness-causing disease,
retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This announcement contains forward-looking statements with
respect to the financial condition, results of operations and
business achievements/performance of ReNeuron and certain of the
plans and objectives of management of ReNeuron with respect
thereto. These statements may generally, but not always, be
identified by the use of words such as "should", "expects",
"estimates", "believes" or similar expressions. This announcement
also contains forward-looking statements attributed to certain
third parties relating to their estimates regarding the growth of
markets and demand for products. By their nature, forward-looking
statements involve risk and uncertainty because they reflect
ReNeuron's current expectations and assumptions as to future events
and circumstances that may not prove accurate. A number of factors
could cause ReNeuron's actual financial condition, results of
operations and business achievements/performance to differ
materially from the estimates made or implied in such
forward-looking statements and, accordingly, reliance should not be
placed on such statements.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSSLFMLFWSESI
(END) Dow Jones Newswires
May 05, 2017 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024